In the wake of Covid-19, psychedelic-assisted therapy is gaining attention.
Measuring and increasing post-traumatic growth may lead to more rewarding interpersonal relationships, self-esteem, and a more optimistic outlook on life.
Research indicates that ayahuasca promotes sustained decreases in neuroticism and increases in agreeableness and openness.
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
Researchers will examine whether MDMA can offset some of the negative side effects of LSD in a therapeutic setting.
A new study sheds light on cognitive behavioral change mechanisms underlying psychedelic assisted psychotherapy.
Brain scans show that psilocybin modulates claustrum connectivity in brain networks.
A double-blind study reveals that mindfulness meditation practice may amplify the positive effects of psilocybin while reducing the likelihood of a bad trip.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
With the paradigm shift created by psychedelics, a recent study suggests reconsidering the medical model of mental illness.